Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 14/20 | 0.72 |
| ▸ | FFAR4 | Q5NUL3 | 3/20 | 0.72 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.54 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.54 |
| ▸ | PTPRB | P23467 | 1/20 | 0.53 |
| ▸ | CDC25A | P30304 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 1/20 | 0.53 |
| ▸ | PTEN | P60484 | 1/20 | 0.53 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.53 |
| ▸ | PTGFR | P43088 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4840290 | 0.90 | FFAR1 (0.60) | FFAR1FFAR4PLA2G10PLA2G2APTGFR | |
| SCHEMBL7335965 | 0.88 | FFAR1 (0.57) | FFAR1FFAR4PLA2G10PLA2G2ALMNA | |
| SCHEMBL6364918 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4LMNACNR1 | |
| SCHEMBL2411845 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4PTGFRLMNACNR1 | |
| SCHEMBL934610 | 0.85 | FFAR1 (0.55) | FFAR1FFAR4PLA2G10PLA2G2ALMNA | |
| SCHEMBL1246091 | 0.85 | FFAR1 (0.59) | FFAR1FFAR4PLA2G10PLA2G2APTGFR | |
| SCHEMBL3109008 | 0.84 | FFAR1 (0.54) | FFAR1FFAR4PLA2G10PLA2G2APTGFR | |
| SCHEMBL1550308 | 0.83 | FFAR1 (1.00) | FFAR1FFAR4 | |
| SCHEMBL12646477 | 0.83 | FFAR1 (0.70) | FFAR1FFAR4 | |
| SCHEMBL13018329 | 0.83 | FFAR1 (0.70) | FFAR1FFAR4KEAP1PTPRBCDC25A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1004574-B1 | Process for producing cyanobenzyl compounds | SHOWA DENKO KK (JP) | 2003-03-19 | — | — | EP | claimed |
| CN-120202211-A | Cyclic compounds having selective KRAS inhibition over HRAS and NRAS | 中外制药株式会社 | 2025-06-24 | — | — | CN | disclosed |
| CN-119731195-A | Cyclic compounds having selective inhibition of KRAS over HRAS and NRAS | 中外制药株式会社 | 2025-03-28 | — | — | CN | disclosed |
| CN-116323572-A | 3- (2- (benzo [ D ] thiazol-2-yl) -2- (phenylsulfonylamino) ethyl) benzamide derivatives and related compounds as TMPRSS2 inhibitors for the treatment of viral infections | 塔斯宾医疗公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-112608267-B | Synthetic method of 4-phenyl-2-pyrrolidone | 赣州中能实业有限公司 | 2022-10-25 | — | — | CN | disclosed |
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | EPIGEN BIOSCIENCES, INC. (US) | 2022-08-30 | — | — | US | disclosed |
| CN-114956933-A | Marker containing isotope oxygen atom and preparation method and application thereof | 清华大学 | 2022-08-30 | — | — | CN | disclosed |
| CN-111517902-B | Aerobic oxidation system containing sulfinic acid, sulfonic acid or derivatives thereof and photo-oxidation promoting method thereof | 清华大学 | 2022-06-14 | — | — | CN | disclosed |
| EP-3020717-B1 | P2X4 RECEPTOR ANTAGONIST | NIPPON CHEMIPHAR CO (JP) | 2021-12-15 | — | — | EP | disclosed |
| CN-112608267-A | Synthetic method of 4-phenyl-2-pyrrolidone | 南京艾斯特医药科技有限公司 | 2021-04-06 | — | — | CN | disclosed |
| US-5286252-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| US-5234404-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5108363-A | DIAGNOSIS, EVALUATION AND TREATMENT OF CORONARY ARTERY DISEASE BY EXERCISE SIMULATION USING CLOSED LOOP DRUG DELIVERY OF AN EXERCISE SIMULATING AGENT BETA AGONIST | GENSIA PHARMACEUTICALS, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0235452-B1 | ORGANIC COMPOUNDS AND THEIR PHARMACEUTICAL USE | LILLY INDUSTRIES LIMITED (GB) | 1992-03-18 | — | — | EP | disclosed |
| EP-0329464-A2 | System for the closed-loop administration of an exercise simulating agent | GENSIA, INC. (US) | 1989-08-23 | — | — | EP | disclosed |
| US-4845110-A | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1989-07-04 | — | — | US | disclosed |
| EP-0219961-B1 | IRREVERSIBLE DOPAMINE-B-HYDROXYLASE INHIBITORS | SMITHKLINE BECKMAN CORPORATION (US) | 1989-03-08 | — | — | EP | disclosed |
| US-4760089-A | Benzonitrile derivative; enzyme inhibitor | SMITHKLINE BECKMAN CORPORATION (US) | 1988-07-26 | — | — | US | disclosed |
| EP-0235452-A2 | Organic compounds and their pharmaceutical use | LILLY INDUSTRIES LIMITED (GB) | 1987-09-09 | — | — | EP | disclosed |
| EP-0219961-A1 | Irreversible dopamine-B-hydroxylase inhibitors | SMITHKLINE BECKMAN CORPORATION (US) | 1987-04-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11427552-B2 | Heterocyclic compounds useful in the treatment of disease | LPAR1, LPAR4, LPAR3 | FFAR1 10/4885FFAR4 14/4885KEAP1 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.